These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24275677)

  • 1. Differing effects of denosumab and alendronate on cortical and trabecular bone.
    Zebaze RM; Libanati C; Austin M; Ghasem-Zadeh A; Hanley DA; Zanchetta JR; Thomas T; Boutroy S; Bogado CE; Bilezikian JP; Seeman E
    Bone; 2014 Feb; 59():173-9. PubMed ID: 24275677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.
    Seeman E; Delmas PD; Hanley DA; Sellmeyer D; Cheung AM; Shane E; Kearns A; Thomas T; Boyd SK; Boutroy S; Bogado C; Majumdar S; Fan M; Libanati C; Zanchetta J
    J Bone Miner Res; 2010 Aug; 25(8):1886-94. PubMed ID: 20222106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
    Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
    J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
    Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS
    Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: A post-hoc HR-pQCT study.
    Hu YJ; Chines A; Shi Y; Seeman E; Guo XE
    Bone; 2022 Jan; 154():116187. PubMed ID: 34530172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis.
    Zebaze R; Libanati C; McClung MR; Zanchetta JR; Kendler DL; Høiseth A; Wang A; Ghasem-Zadeh A; Seeman E
    J Bone Miner Res; 2016 Oct; 31(10):1827-1834. PubMed ID: 27082709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
    Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Cortico-Trabecular Transitional Zone Porosity and Reduced Trabecular Density in Men and Women with Stress Fractures.
    Zendeli A; Bui M; Fischer L; Ghasem-Zadeh A; Schima W; Seeman E
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33800284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women.
    Bala Y; Chapurlat R; Cheung AM; Felsenberg D; LaRoche M; Morris E; Reeve J; Thomas T; Zanchetta J; Bock O; Ghasem-Zadeh A; Djoumessi RM; Seeman E; Rizzoli R
    J Bone Miner Res; 2014 Feb; 29(2):380-8. PubMed ID: 24115129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
    Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
    J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images.
    Zebaze R; Ghasem-Zadeh A; Mbala A; Seeman E
    Bone; 2013 May; 54(1):8-20. PubMed ID: 23334082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
    Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
    Genant HK; Libanati C; Engelke K; Zanchetta JR; Høiseth A; Yuen CK; Stonkus S; Bolognese MA; Franek E; Fuerst T; Radcliffe HS; McClung MR
    Bone; 2013 Oct; 56(2):482-8. PubMed ID: 23871852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
    Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
    J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.